A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
Latest Information Update: 25 Oct 2024
At a glance
- Drugs HOB 047 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms HDNO-1605
- Sponsors Hyundai Pharmaceutical
- 25 Oct 2024 New trial record